O. Bolte

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

Olivier Rixe, Ronald M. Bukowski, M. Dror Michaelson et al. · The Lancet Oncology · 2007 · 436 citations

Medicine, Oncology, Pharmacology +14

AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC)

Brian I. Rini, Olivier Rixe, Ronald M. Bukowski et al. · Journal of Clinical Oncology · 2005 · 148 citations

Medicine, Oncology, Pharmacology +17

Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group

P. Schöffski, S. Riggert, P. Fumoleau et al. · Annals of Oncology · 2004 · 80 citations · Full text

Medicine, Oncology, Pharmacology +10

Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer

Patrick Schöffski, B. Thate, Gernot Beutel et al. · Annals of Oncology · 2004 · 66 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +6

Radioimmunotherapy with [188Re]-labelled anti-CD66 antibody in the conditioning for allogeneic stem cell transplantation for high-risk acute myeloid leukemia

Christian Koenecke, Michael Hofmann, O. Bolte et al. · International Journal of Hematology · 2008 · 31 citations

Medicine, Hematology, Immunology +16